依库珠单抗控制阵发性睡眠性血红蛋白尿症的溶血危机
杨慧， 隋秀芳， 方宝枝， 张婷， 徐金格， 吕明恩… - 临床血液学杂志, 2024 - whuhzzs.com
目的末端补体C5 抑制剂依库珠单抗(eculizumab) 被推荐为阵发性睡眠性血红蛋白尿症(
paroxysmal nocturnal hemoglobinuria, PNH) 的一线治疗方案. 本研究探索了21 例PNH …
paroxysmal nocturnal hemoglobinuria, PNH) 的一线治疗方案. 本研究探索了21 例PNH …
Stable responses to danicopan as add-on to ravulizumab in two patients with paroxysmal nocturnal hemoglobinuria
W Füreder, P Valent - Annals of Hematology, 2024 - Springer
Table 1 Patient characteristics-patient 1 BL* w 1 w 2 w 3 w5 w7 w10 w12 w15 w17 w19
Hemoglobin, g/dL 7.8 11.1 11.5 11.5 11.5 11.3 10.6 10.8 10.7 10.9 11.2 FACIT fatigue score …
Hemoglobin, g/dL 7.8 11.1 11.5 11.5 11.5 11.3 10.6 10.8 10.7 10.9 11.2 FACIT fatigue score …
Thrombosis in PNH: largely gone, but not forgotten
J Szer - Blood, 2024 - ashpublications.org
The most dramatic and lifesaving consequence of the introduction of effective therapy for
paroxysmal nocturnal hemoglobinuria (PNH) was a marked reduction in thrombosis risk. In …
paroxysmal nocturnal hemoglobinuria (PNH) was a marked reduction in thrombosis risk. In …
[PDF][PDF] Direct Oral Anticoagulants and Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Update on Evidence
Paroxysmal nocturnal hemoglobinuria (PNH) is a hematological disorder with an elevated
risk of thrombosis. The primary cause of death in PNH patients is thrombosis. Thrombosis in …
risk of thrombosis. The primary cause of death in PNH patients is thrombosis. Thrombosis in …
Efficacy of eculizumab in hemolytic crisis of paroxysmal nocturnal hemoglobinuria
Y Hui, SUI Xiufang, F Baozhi, Z Ting, XU Jinge… - J Clin …, 2024 - lcxyen.whuhzzs.com
Efficacy of eculizumab in hemolytic crisis of paroxysmal nocturnal hemoglobinuria
Homepage Journals 1.{{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} …
Homepage Journals 1.{{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} …